Financial Performance - The company achieved a revenue of 579.67 million in 2021, with a sales proportion to its largest customer, Sinopec, at 30.42%[15]. - The company's operating revenue for 2021 was CNY 579,665,590.80, representing a year-over-year increase of 4.34% compared to CNY 555,555,725.44 in 2020[36]. - The net profit attributable to shareholders decreased by 4.66% to CNY 60,640,445.07 in 2021 from CNY 63,602,931.34 in 2020[36]. - The gross profit margin declined to 25.71% in 2021 from 31.60% in 2020[36]. - The company's cash and cash equivalents increased by 462.03% to approximately ¥250.69 million, primarily due to a public stock issuance that raised net funds of ¥237.74 million[69]. - The company reported a significant impact on production and delivery due to strict pandemic control measures in its operational area, which may affect profitability[135]. - The company reported a total revenue of 3,506,162, with a net profit of 3,454,511, reflecting a growth of 2.49%[173]. Research and Development - The company obtained 9 new patents during the reporting period, including 3 invention patents and 6 utility model patents, enhancing its innovation capabilities[8]. - The company holds 42 patents as of December 31, 2021, including 18 invention patents and 24 utility model patents, reflecting ongoing investment in R&D[17]. - The company plans to enhance its research and development efforts, focusing on new product development and project construction, with a target of launching a 10,000 tons/year catalyst new materials and high-end catalyst project in 2022[121]. - R&D expenditure amounted to 22,352,472.65, representing 3.86% of operating revenue[104]. - During the reporting period, the company conducted 18 R&D projects with an expenditure of 22.35 million, achieving significant results in new product development and process optimization[107]. Market and Sales - The company’s revenue from the petrochemical industry represented 64.31% of total sales in 2021, highlighting its dependency on this sector[16]. - The company’s export sales accounted for 38.98% of its main business revenue in 2021, indicating a significant reliance on overseas markets[16]. - The proportion of export revenue increased from 26.96% to 38.98%, with export revenue reaching 225.96 million yuan, a growth of 50.86%[58]. - The company’s major customer, China Petroleum & Chemical Corporation, accounted for 36.20% of total sales, with total sales to the top five customers representing 86.45% of total sales[84]. - The company is responding to national energy conservation and environmental protection policies, which are expected to create significant opportunities for molecular sieve enterprises in high-energy-consuming industries[120]. Risks and Challenges - The company faces risks related to environmental regulations and potential increases in compliance costs due to stricter standards[16]. - The company faces risks related to the implementation of fundraising projects, which require significant investment and may not yield expected economic benefits if market demand decreases[19]. - The company is facing risks related to its dependence on Sinopec and potential impacts from changes in the macroeconomic environment or the petrochemical industry[124]. - The company is actively monitoring exchange rate fluctuations, as its export business is settled in USD, which could impact financial performance if the RMB depreciates significantly[130]. - The company has established a comprehensive safety management system to mitigate risks associated with hazardous materials used in production[126]. Shareholder and Equity Information - The largest shareholder holds 8.94% of the company's shares, with the top eight shareholders collectively holding 13.66%, highlighting potential control risks[18]. - The total share capital of the company is 138,763,865 shares[31]. - The company has no controlling shareholder, with the actual controller being a group of individuals including Mingyuexin and Li Chengguang[30]. - The company has maintained a stable control structure with eight actual controllers signing a unified action agreement to ensure consistent decision-making[177]. - The company has committed to timely and effectively compensate for any dilution of earnings per share resulting from public offerings, ensuring shareholder returns[156]. Assets and Liabilities - Total assets increased by 49.03% to CNY 972,018,824.47 at the end of 2021, compared to CNY 652,220,999.58 at the end of 2020[38]. - The company's debt-to-asset ratio (consolidated) improved to 24.64% in 2021 from 31.04% in 2020[38]. - The company reported accounts receivable of 160.20 million at the end of the reporting period, indicating potential credit risk[16]. - Inventory value reached 140,127.8 thousand yuan, representing 23.17% of current assets, indicating potential risks related to inventory management[17]. - The company has outstanding loans totaling ¥29,750,000, with interest rates of 5.50% and 5.17% for different loans[189]. Future Outlook and Strategy - The company plans to continue expanding its product and technology development efforts to enhance its market position[8]. - The company plans to focus on the development of environmentally friendly materials, particularly in automotive exhaust treatment, indicating a strategic shift in business focus[18]. - The company aims to strengthen its competitive edge in the industry by continuously improving product performance and optimizing manufacturing processes for environmental catalytic molecular sieves[118]. - The company is exploring potential mergers and acquisitions to further enhance its market position, but no specific targets were mentioned[174]. - The company’s future outlook remains positive, with expectations for continued growth in revenue and market share[174].

Financial Performance - Operating revenue for the first quarter reached CNY 164,976,203.10, an increase of 11.46% year-on-year[15] - Net profit attributable to shareholders decreased by 27.79% to CNY 11,675,274.18 compared to the same period last year[15] - The company’s basic earnings per share decreased by 42.86% to CNY 0.08 compared to the previous year[15] - Total revenue for Q1 2022 reached ¥164,976,203.10, an increase of 11.9% compared to ¥148,008,540.17 in Q1 2021[42] - Net profit for Q1 2022 was ¥11,675,274.18, a decrease of 27.8% from ¥16,169,257.11 in Q1 2021[44] - Operating profit for Q1 2022 was ¥3,228,654.45, down from ¥4,643,979.53 in Q1 2021, indicating a decline of about 30.6%[46] - Total comprehensive income for Q1 2022 was ¥2,742,593.49, down from ¥3,973,724.92 in Q1 2021, showing a decline of about 30.9%[47] Assets and Liabilities - Total assets increased by 5.17% to CNY 1,022,252,621.12 compared to the end of the previous year[15] - The company's total liabilities to assets ratio increased to 27.14% from 24.64% year-on-year[15] - The company's total liabilities increased to CNY 277,477,963.80 from CNY 239,472,523.53, reflecting an increase of about 15.9%[36] - Total assets increased to ¥670,215,648.27 in 2022 from ¥637,948,249.40 in 2021, representing a growth of 5.2%[40] - Total liabilities rose to ¥141,932,723.10 in 2022, compared to ¥112,936,804.42 in 2021, indicating an increase of 25.7%[40] Cash Flow - Cash flow from operating activities improved significantly, with a net inflow of CNY 4,059,428.74, a 118.63% increase from the previous year[15] - Cash flow from operating activities for Q1 2022 was ¥4,059,428.74, a significant improvement from a negative cash flow of ¥21,788,557.76 in Q1 2021[48] - Investment activities generated a net cash outflow of ¥2,057,344.68 in Q1 2022, compared to a net outflow of ¥5,282,099.50 in Q1 2021, showing an improvement[49] - Financing activities produced a net cash inflow of ¥15,898,876.10 in Q1 2022, a decrease from ¥251,864,648.03 in Q1 2021[49] Expenses - Sales expenses decreased by 48.08% to CNY 912,162.02, attributed to personnel adjustments[17] - Financial expenses increased significantly by 385.10% to CNY 323,362.55, mainly due to exchange losses and increased borrowing costs[17] - Operating costs for Q1 2022 were ¥149,910,010.49, up from ¥128,327,462.35 in Q1 2021, reflecting a rise of 16.8%[42] - Research and development expenses for Q1 2022 were ¥4,625,539.28, a decrease of 13.5% from ¥5,351,005.92 in Q1 2021[43] Shareholder Information - The total number of ordinary shares at the end of the period is 138,763,865, with no changes during the reporting period[21] - The proportion of unrestricted shares held by the controlling shareholder remains at 78.80%[21] - The total number of shareholders is 7,243[21] - The total number of restricted shares held by the controlling shareholder is 18,961,351, representing 13.66% of total shares[21] - The number of shareholders holding more than 5% of shares includes 明曰信 with 12,408,249 shares (8.94%) and 山东兴华建设集团 with 5,803,200 shares (4.18%)[23] Other Information - The company has provided guarantees for its wholly-owned subsidiaries, as disclosed in the announcement[28] - The company has not engaged in any significant asset acquisitions or mergers during the reporting period[28] - There are no outstanding lawsuits or arbitration matters against the company[28] - The company has fulfilled its disclosed commitments in a timely manner[28] - The company has not implemented any profit distribution or capital reserve transfer during the reporting period[31]